Pulmonary eosinophilia associated to treatment with natalizumab

Natalizumab (Tysabri®) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who starte...

Full description

Saved in:
Bibliographic Details
Published inAnnals of thoracic medicine Vol. 11; no. 3; pp. 224 - 226
Main Authors Curto, Elena, Munteis-Olivas, Elvira, Balcells, Eva, Dominguez-Alvarez, M
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow Publications 01.07.2016
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Medknow Publications & Media Pvt Ltd
Wolters Kluwer Medknow Publications
Subjects
Asthma
Care and treatment
Case Report
Complications and side effects
Conflicts of interest
Development and progression
Dyspnea
Medical imaging
Multiple sclerosis
Natalizumab
Neutrophils
Parasites
Patients
Pulmonary eosinophilia
Streptococcus infections
Multiple sclerosis
pulmonary eosinophilia
natalizumab
Online AccessGet full text

Cover

More Information
Summary:Natalizumab (Tysabri®) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who started treatment with natalizumab. She began to show mild asthmatic symptoms until she needed admission to the hospital due to respiratory insufficiency. Blood tests showed peripheral eosinophilia and the thoracic computed tomography scan demonstrated pulmonary infiltrates. The bronchoscopy with the bronchoalveolar lavage resulted in eosinophilic alveolitis. No evidence of bacterial, fungal and parasitic infection, connective tissue disease, or vasculitis were observed. After discontinuation of natalizumab, the patient improved without other treatments. As MS is a prevalent disease and the use of natalizumab is increasing, we consider important to point out that this drug can be associated with pulmonary eosinophilia, especially in patients with allergic rhinoconjunctivitis or asthma.
ISSN:1817-1737
1998-3557
DOI:10.4103/1817-1737.185762